Table 2.

MR analyses between exposures (PUFAs) and outcome (PD Risk).

	Exposure	N	Inverse variance weighted			MR-Egger
			OR	95%CI	Value of p	OR	95%CI	Value of p
omega-6 PUFAs	AA	31	1.03	1.01–1.04	2.24E-04*	1.03	1.01–1.05	0.03
	MVMR-AA	31	1.03	1.02–1.04	6.15E-08*
	strict-AA	19	1.03	1.01–1.05	5.88E-04*	1.04	1.01–1.07	0.03
	LA	54	1.00	0.99–1.00	0.71	1.00	0.99–1.01	0.64
	MVMR-LA	54	1.00	0.99–1.00	0.49
	strict-LA	37	1.00	1.00–1.01	0.73	1.00	0.99–1.02	0.47
omega-3 PUFAs	DHA	6	1.00	0.76–1.23	0.97	0.93	−0.59 to 2.45	0.93
	MVMR-DHA	6	0.99	0.74–1.24	0.93
	EPA	4	1.00	0.83–1.17	0.99	1.06	0.83–1.30	0.66
	MVMR-EPA	4	1.05	1.01–1.08	5.40E-03*
	DPA	2	0.96	0.56–1.37	0.86	–
	ALA	1	1.21	−0.99 to 3.40	0.85	–
	Exposure	N	Weighted median			Weighted mode
			OR	95%CI	Value of p	OR	95%CI	Value of p
omega-6 PUFA	AA	31	1.02	1.00–1.04	0.02	1.03	1.01–1.05	0.02
	strict-AA	19	1.03	1.01–1.06	8.12E-03*	1.03	1.00–1.06	0.04
	LA	54	1.00	0.99–1.00	0.56	1.00	0.99–1.01	0.88
	strict-LA	37	1.00	0.99–1.01	0.87	1.00	0.99–1.01	0.61
omega-3 PUFA	DHA	6	0.94	0.72–1.16	0.59	0.93	0.71–1.15	0.56
	EPA	4	1.02	0.83–1.21	0.81	1.03	0.84–1.23	0.77
	DPA	2			–	–		–
	ALA	1			–	–		–

MR, Mendelian randomization; PUFA, polyunsaturated fatty acid; PD, Parkinson’s disease; MVMR, multivariable Mendelian randomization; MR-Egger, Mendelian randomization Egger regression; N, number of SNPs included; OR, odds ratio; CI, confidence interval; AA, arachidonic acid; LA, linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; ALA, alpha-linolenic acid. *Results with a significant p-value after false discovery rate correction.